Intrapleural therapy

Respirology

Volumn 16, Issue 6, 2011, Pages 891-899

  Huggins, J Terrill ^a   Doelken, Peter ^a   Sahn, Steven A ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

fibrinolytic; indwelling pleural catheter; intrapleural therapy; pleurodesis; sclerosant

Indexed keywords

ALTEPLASE; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA INTERFERON; BLEOMYCIN; CISPLATIN; DEOXYRIBONUCLEASE; DOXORUBICIN; DOXYCYCLINE; ETOPOSIDE; FIBRIN; FIBRINOLYTIC AGENT; FLUOROURACIL; MEPACRINE; METHYLPREDNISOLONE ACETATE; MINOCYCLINE; MITOMYCIN C; MITOXANTRONE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; POVIDONE IODINE; SCLEROSING AGENT; STAPHYLOCOCCAL SUPERANTIGEN; STREPTODORNASE; STREPTOKINASE; SUPERANTIGEN; TALC; TETRACYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROKINASE;

ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; ANTIBIOTIC THERAPY; ARTICLE; ATELECTASIS; BACTERIAL GENE; CANCER SURVIVAL; CATHETER; CATHETERIZATION; CHEMICAL PLEURODESIS; COCHRANE LIBRARY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG FEVER; DRUG INSTILLATION; DYSPNEA; EMPYEMA; FIBRINOLYTIC THERAPY; GENE CLUSTER; HEMATOTHORAX; HOSPITALIZATION; HUMAN; INDWELLING CATHETER; LUNG NON SMALL CELL CANCER; METHODOLOGY; MULTICENTER STUDY (TOPIC); NONHUMAN; PALLIATIVE THERAPY; PATIENT SELECTION; PLEURA DISEASE; PLEURA EFFUSION; PLEURA EMPYEMA; PLEURA FLUID; PLEURISY; PLEURODESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEPSIS; SYSTEMATIC REVIEW (TOPIC); THORACOTOMY; THORAX PAIN; TREATMENT OUTCOME;

CARCINOMA, NON-SMALL-CELL LUNG; CATHETERS, INDWELLING; DEOXYRIBONUCLEASES; DYSPNEA; FIBRINOLYTIC AGENTS; HUMANS; LUNG NEOPLASMS; PLEURAL DISEASES; PLEURODESIS; SCLEROSING SOLUTIONS; STREPTOKINASE; SUPERANTIGENS;

EID: 79960828382     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2011.02011.x     Document Type: Article

References (114)

1. Heffner JE, Klein JS,. Recent advances in the diagnosis and management of malignant pleural effusions. Mayo Clin. Proc. 2008; 83: 235-50. (Pubitemid 351303104)
2. Sahn SA,. Management of complicated parapneumonic effusions. Am. Rev. Respir. Dis. 1993; 148: 813-17. (Pubitemid 23263798)
3. Tillett WS, Sherry S,. The effect in patients with streptococcal fibrinolysis (streptokinase) and streptococcal desoxyribonuclease on fibrinous, purulent, and sanguinous pleural exudations. J. Clin. Invest. 1949; 28: 173-90.
4. Walker-Renard PB, Vaughan LM, Sahn SA,. Chemical pleurodesis for malignant pleural effusions. Ann. Intern. Med. 1994; 120: 56-64. (Pubitemid 24011502)
5. Sahn SA,. Malignant pleural effusions. Semin. Respir. Crit. Care Med. 2001; 22: 607-16.
6. Sahn SA,. Talc should be used for pleurodesis. Am. J. Respir. Crit. Care Med. 2000; 162: 2023-4. (Pubitemid 32051655)
7. Sahn SA,. Management of malignant pleural effusions. Monaldi Arch. Chest Dis. 2001; 56: 394-9. (Pubitemid 34134118)
8. Antony VB, Loddenkemper R, Astoul P, et al,. Management of malignant pleural effusions. Eur. Respir. J. 2001; 18: 402-19. (Pubitemid 32776419)
9. Terman DS, Bohach G, Vandenesch F, et al,. Staphylococcal superantigens of the enterotoxin gene cluster (egc) for treatment of stage IIIb non-small cell lung cancer with pleural effusions. Clin. Chest Med. 2006; 27: 321-34. (Pubitemid 43744479)
10. Chu FS, Thadhani K, Schantz EJ, et al,. Purification and characterization of staphylococcal enterotoxin A. Biochemistry 1966; 5: 3281-9.
11. Marrack P, Kappler J,. The staphylococcal enterotoxins and their relatives. Science 1990; 248: 1066-72.
12. Ren S, Terman DS, Bohach G, et al,. Intrapleural staphylococcal superantigen induces resolution of malignant pleural effusions and a survival benefit in non-small cell lung cancer. Chest 2004; 126: 1529-39. (Pubitemid 39525027)
13. Proft T, Fraser JD,. Bacterial superantigens. Clin. Exp. Immunol. 2003; 133: 299-306. (Pubitemid 37051503)
14. Pollak JS,. Malignant pleural effusions: treatment with tunneled long-term drainage catheters. Curr. Opin. Pulm. Med. 2002; 8: 302-7. (Pubitemid 34625964)
15. Verfaillie G, Herreweghe RV, Lamote J, et al,. Use of a Port-a-Cath system in the home setting for the treatment of symptomatic recurrent malignant pleural effusion. Eur. J. Cancer Care 2005; 14: 182-4. (Pubitemid 40655737)
16. Alisky JM,. Implantable central venous access ports for minimally invasive repetitive drainage of pleural effusions. Med. Hypotheses 2007; 68: 910-11. (Pubitemid 46136807)
17. Putnam JJB, Light RW, Rodriguez RM, et al,. A randomized comparsion of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions. Cancer 1999; 86: 1992-9.
18. Putnam JB Jr, Walsh GL, Swisher SG, et al,. Outpatient management of malignant pleural effusion by chronic indwelling pleural catheter. Ann. Thorac. Surg. 2000; 69: 369-75. (Pubitemid 30125561)
19. van den Toorn LM, Schaap E, Surmont VF, et al,. Management of recurrent malignant pleural effusions with a chronic indwelling pleural catheter. Lung Cancer 2005; 50: 123-7. (Pubitemid 41297479)
20. Pollak JS, Burdge CM, Rosenblatt M, et al,. Treatment of malignant pleural effusions with tunneled long-term drainage catheters. J. Vasc. Interv. Radiol. 2001; 12: 201-8. (Pubitemid 32167782)
21. Tremblay A, Michaud G,. Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion. Chest 2006; 129: 362-8. (Pubitemid 43289856)
22. Pien GW, Gant MJ, Washam CL, et al,. Use of an implantable pleural catheter for trapped lung syndrome in patients with malignant pleural effusion. Chest 2001; 119: 1641-6. (Pubitemid 32744916)
23. Musani AI, Haas AR, Seijo L, et al,. Outpatient management of malignant pleural effusions with small-bore, tunneled pleural catheters. Respiration 2004; 71: 559-66. (Pubitemid 40091427)
24. Ohm C, Park D, Vogen M, et al,. Use of an indwelling pleural catheter compared with thorascopic talc pleurodesis in the management of malignant pleural effusions. Am. Surg. 2003; 69: 198-202.
25. Wachsman AM, Hoffer EK, Forauer AR, et al,. Tension pneumothorax after placement of a tunneled pleural drainage catheter in a patient with recurrent malignant pleural effusions. Cardiovasc. Intervent. Radiol. 2007; 30: 531-3. (Pubitemid 46599116)
26. Davies RJ, Traill ZC, Gleeson FV,. Randomised controlled trial of intrapleural streptokinase in community acquired pleural infections. Thorax 1997; 52: 416-21.
27. Bouros D, Schiza S, Tzanakis N, et al,. Intrapleural urokinase versus normal saline in the treatment of complicated parapneumonic effusions and empyema. A randomized, double-blind study. Am. J. Respir. Crit. Care Med. 1999; 159: 37-42. (Pubitemid 29036500)
28. Lim TK, Chin NK,. Empirical treatment with fibrinolysis and early surgery reduces the duration of hospitalization in pleural sepsis. Eur. Respir. J. 1999; 13: 514-18. (Pubitemid 29180157)
29. Tuncozgur B, Ustunsoy H, Sivrikoz MC, et al,. Intrapleural urokinase in the management of parapneumonic empyema: a randomised controlled trial. Int. J. Clin. Pract. 2001; 55: 658-60. (Pubitemid 34023826)
30. Diacon AH, Theron J, Schuurmans MM, et al,. Intrapleural streptokinase for empyema and complicated parapneumonic effusions. Am. J. Respir. Crit. Care Med. 2004; 170: 49-53. (Pubitemid 38997750)
31. Maskell NA, Davies CW, Nunn AJ, et al,. U.K. Controlled trial of intrapleural streptokinase for pleural infection. N. Engl. J. Med. 2005; 352: 865-74. (Pubitemid 40300295)
32. Taylor RFH, Rubens MB, Pearson MC, et al,. Intrapleural streptokinase in the management of empyema. Thorax 1994; 49: 856-9. (Pubitemid 24287477)
33. Henke CA, Leatherman JW,. Intrapleurally administered streptokinase in the treatment of acute loculated nonpurulent parapneumonic effusions. Am. Rev. Respir. Dis. 1992; 145: 680-4.
34. Bouros D, Schiza S, Panagou P, et al,. Role of streptokinase in the treatment of acute loculated parapneumonic pleural effusions and empyema. Thorax 1994; 49: 852-5. (Pubitemid 24287476)
35. Jerjes Sanchez C, Ramirez Rivera A, Elizalde JJ, et al,. Intrapleural fibrinolysis with streptokinase as an adjunctive treatment in hemothorax and empyema: a multicenter trial. Chest 1996; 109: 1514-19. (Pubitemid 26193377)
36. Temes RT, Follis F, Kessler RM, et al,. Intrapleural fibrinolytics in management of empyema thoracis. Chest 1996; 110: 102-6. (Pubitemid 26249309)
37. Moulton JS, Benkert RE, Weisiger KH, et al,. Treatment of complicated pleural fluid collections with image-guided drainage and intracavitary urokinase. Chest 1995; 108: 1252-9.
38. Thomson AH, Hull J, Kumar MR, et al,. Randomised trial of intrapleural urokinase in the treatment of childhood empyema. Thorax 2002; 57: 343-7. (Pubitemid 34298933)
39. Light RW, Nguyen T, Mulligan ME, et al,. The in vitro efficacy of varidase versus streptokinase or urokinase for liquefying thick purulent exudative material from loculated empyema. Lung 2000; 178: 13-18. (Pubitemid 30111713)
40. Simpson G, Roomes D, Heron M,. Effects of streptokinase and deoxyribonuclease on viscosity of human surgical and empyema pus. Chest 2000; 117: 1728-33. (Pubitemid 30413370)
41. Simpson G, Roomes D, Reeves B,. Successful treatment of empyema thoracis with human recombinant deoxyribonuclease. Thorax 2003; 58: 365-6. (Pubitemid 36411427)
42. Fujiwara K, Yasumitsu T, Nakagawa K, et al,. Intrapleural streptokinase-streptodornase in the treatment of empyema and hemothorax. Kyobu Geka 2002; 55: 1115-19.
43. Sudduth CD, Sahn SA,. Pleurodesis for nonmalignant pleural effusions recommendations. Chest 1992; 102: 1855-60. (Pubitemid 23001242)
44. Adler RH, Levinsky L,. Persistent chylothorax. Treatment by talc pleurodesis. J. Thorac. Cardiovasc. Surg. 1978; 76: 859-64. (Pubitemid 9084855)
45. Jenkins PG, Shelp WD,. Recurrent pleural transudate in the nephrotic syndrome. JAMA 1974; 230: 587-8.
46. Kaine JL,. Refractory massive pleural effusion in systemic lupus erythematosus treated with talc poudrage. Ann. Rheum. Dis. 1988; 47: 1031-2.
47. Spicer AJ, Fisher JA,. Recurring pleural effusion in congestive heart failure treated by pleurodesis. J. Ir. Med. Assoc. 1969; 383: 177-8.
48. Townsend R, Fragula J,. Hydrothorax in a patient receiving continuous ambulatory peritoneal dialysis. Arch Intern Med. 1982; 142: 1571-2.
49. Taylor JR, Ryu J, Colby TV, et al,. Lymphangioleiomyomatosis: clinical course in 32 patients. N. Engl. J. Med. 1990; 323: 1254-60. (Pubitemid 20366532)
50. Lan R-S, Lo SK, Chuang M-L, et al,. Elastance of the pleural space: a predictor for the outcome of pleurodesis in patients with malignant pleural effusion. Ann. Intern. Med. 1997; 126: 768-74. (Pubitemid 27209642)
51. Doelken P, Huggins JT, Pastis N, et al,. Pleural manometry: technique and clinical implications. Chest 2004; 126: 1764-9. (Pubitemid 39643977)
52. Huggins JT, Doelken P,. Pleural manometry. Clin. Chest Med. 2006; 27: 229-40. (Pubitemid 43729185)
53. Antony VB, Loddenkemper R, Astoul P, et al,. Statement of the American Thoracic Society: management of malignant pleural effusions. Am. J. Respir. Crit. Care Med. 2000; 162: 1987-2001.
54. Heffner JE, Neitert PJ, Barbieri C,. Pleural fluid pH as a predictor of pleurodesis failure. Chest 2000; 117: 87-95. (Pubitemid 30053625)
55. Good JT, Taryler DA, Sahn SA,. The pathogenesis of low glucose, low pH malignant effusions. Am. Rev. Respir. Dis. 1985; 131: 737-41. (Pubitemid 15066860)
56. Walker-Renard PG, Vaughn LM, Sahn SA,. Chemical pleurodesis for malignant pleural effusions. Ann. Intern. Med. 1994; 120: 56-64. (Pubitemid 24011502)
57. Yildirim H, Metintas M, Ak G, et al,. Predictors of talc pleurodesis outcome in patients with malignant pleural effusions. Lung Cancer 2008; 62: 139-44.
58. Sorensen PG, Svendsen TL, Enk B,. Treatment of malignant pleural effusion with drainage, with and without instillation of talc. Eur. J. Respir. Dis. 1984; 65: 131-5. (Pubitemid 14188709)
59. Kennedy L, Harley RA, Sahn SA, et al,. Talc slurry pleurodesis: pleural fluid and histologic analysis. Chest 1995; 107: 1707-12.
60. Schulze M, Boehle AS, Kurdow R, et al,. Effective treatment of malignant pleural effusion by minimal invasive thoracic surgery: thoracoscopic talc pleurodesis and pleuroperitoneal shunts in 101 patients. Ann. Thorac. Surg. 2001; 7: 1809-12. (Pubitemid 32554405)
61. Jones GR,. Treatment of recurrent malignant pleural effusion by iodized talc pleurodesis. Thorax 1969; 24: 69-73.
62. Dresler CM, Olak J, Herndon JE, et al,. Cooperative Groups Cancer and Leukemia Group B, Eastern Cooperative Oncology Group, North Central Cooperative Oncology Group, Radiation Oncology Therapy Group. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest 2005; 127: 909-15.
63. Bernard A, de Dompsure RB, Hagry O, et al,. Early and late mortality after pleurodesis for malignant pleural effusion. Ann. Thorac. Surg. 2002; 74: 213-17. (Pubitemid 34734673)
64. Gasparri R, Leo F, Veronesi G, et al,. Video-assisted management of malignant pleural effusion in breast carcinoma. Cancer 2006; 106: 271-6. (Pubitemid 43100433)
65. Arapis K, Caliandro R, Stern JB, et al,. Thoracoscopic palliative treatment of malignant pleural effusions: results in 273 patients. Surg. Endosc. 2006; 20: 919-23. (Pubitemid 43825198)
66. Paschoalini Mda S, Vargas FS, Marchi E, et al,. Prospective randomized trial of silver nitrate vs talc slurry in pleurodesis for symptomatic malignant pleural effusions. Chest 2005; 128: 684-9. (Pubitemid 41140496)
67. Marrazzo A, Noto A, Casa L, et al,. Video-thoracoscopic surgical pleurodesis in the management of malignant pleural effusion: the importance of an early intervention. J. Pain Symptom Manage. 2005; 30: 75-9. (Pubitemid 41021682)
68. Kolschmann S, Ballin A, Gillissen A,. Clinical efficacy and safety of thoracoscopic talc pleurodesis in malignant pleural effusions. Chest 2005; 128: 1431-5. (Pubitemid 41324428)
69. Kilic D, Akay H, Kavukcu S, et al,. Management of recurrent malignant pleural effusion with chemical pleurodesis. Surg. Today. 2005; 35: 634-8. (Pubitemid 41032282)
70. Stefani A, Natali P, Casali C, et al,. Talc poudrage versus talc slurry in the treatment of malignant pleural effusion: a prospective comparative study. Eur. J. Cardiothorac. Surg. 2006; 30: 827-32. (Pubitemid 44738626)
71. Goodman A, Davies CW,. Efficacy of short-term versus long-term chest tube drainage following talc slurry pleurodesis in patients with malignant pleural effusions: a randomised trial. Lung Cancer 2006; 54: 51-5.
72. Mager HJ, Maesen B, Verzijlbergen F, et al,. Distribution of talc suspension during treatment of malignant pleural effusion with talc pleurodesis. Lung Cancer 2002; 36: 77-81. (Pubitemid 34224899)
73. Dryzer SR, Allen ML, Strange C, et al,. A comparison of rotation and nonrotation in tetracycline pleurodesis. Chest 1993; 104 (6): 1763-6. Eur J Cardiothorac Surg. 2006 May;29:829-838. Epub 2006 Apr 12. (Pubitemid 23360108)
74. Teixeira LR, Vargas FS, Acencio MM, et al,. Influence of anti-inflammatory drugs (methylprednisolone and diclofenac sodium) on experimental pleurodesis induced by silver nitrate or talc. Chest 2005; 128 (6): 4041-5. (Pubitemid 43062670)
75. Teixeira LR, Wu W, Chang DS, et al,. The effect of corticosteroids on pleurodesis induced by doxycycline in rabbits. Chest 2002; 121 (1): 216-19. (Pubitemid 34114250)
76. Xie C, Teixeira LR, McGovern JP, et al,. Systemic corticosteroids decrease the effectiveness of talc pleurodesis. Am. J. Respir. Crit. Care Med. 1998; 157: 1441-4.
77. Hsu LH, Soong TC, Feng AC, et al,. Intrapleural urokinase for the treatment of loculated malignant pleural effusions and trapped lungs in medically inoperable cancer patients. J. Thorac. Oncol. 2006; 1: 460-7. (Pubitemid 47181424)
78. Porcel JM, Salud A, Nabal M, et al,. Rapid pleurodesis with doxycycline through a small-bore catheter for the treatment of metastatic malignant effusions. Support. Care Cancer 2006; 14: 475-8.
79. Heffner JE, Standerfer RJ, Torstveit J, et al,. Clinical efficacy of doxycycline for pleurodesis. Chest 1994; 105: 1743-7. (Pubitemid 24180662)
80. Kuzdzal J, Sladek K, Wasowski D, et al,. Talc powder vs doxycycline in the control of malignant pleural effusion: a prospective, randomized trial. Med. Sci. Monit. 2003; 9: I54-9.
81. Bielsa S, Hernández P, Rodriguez-Panadero F, et al,. Tumor type influences the effectiveness of pleurodesis in malignant effusions. Lung 2011; 189: 151-5.
82. Sartori S, Tassinari D, Ceccotti P, et al,. Prospective randomized trial of intrapleural bleomycin versus interferon alfa-2b via ultrasound-guided smallbore chest tube in the palliative treatment of malignant pleural effusions. J. Clin. Oncol. 2004; 22: 1228-33. (Pubitemid 41079836)
83. Moffett MJ, Ruckdeschel JC,. Bleomycin and tetracycline in malignant pleural effusions: a review. Semin. Oncol. 1992; 19 (2 Suppl. 5): 59-62.
84. Ukale V, Agrenius V, Hillerdal G, et al,. Pleurodesis in recurrent pleural effusions: a randomized comparison of a classical and a currently popular drug. Lung Cancer 2004; 43: 323-8. (Pubitemid 38224153)
85. Stiksa G, Korsgaard R, Simonsson BG,. Treatment of recurrent pleural effusion by pleurodesis with quinacrine: comparison between instillation by repeated thoracenteses and by tube drainage. Scand. J. Respir. Dis. 1979; 60: 197-205. (Pubitemid 10193543)
86. Baly TC, Kisner DL, Sybert A, et al,. Tetracycline and quinacrine in the control of malignant pleural effusions: a randomized trial. Cancer 1978; 41: 1188-92. (Pubitemid 8312212)
87. Koldsland S, Svennevig JL, Lehne G, et al,. Chemical pleurodesis in malignant pleural effusions: a randomized prospective study of mepacrine versus bleomycin. Thorax 1993; 48: 790-3. (Pubitemid 23244339)
88. Banerjee AK, Willetts I, Robertson JF, et al,. Pleural effusion in breast cancer: a review of the Nottingham experience. Eur. J. Surg. Oncol. 1994; 20: 33-6. (Pubitemid 24104946)
89. Olivares-Torres CA, Laniado-Laborin R, Chavez-Garcia C, et al,. Iodopovidone pleurodesis for recurrent pleural effusions. Chest 2002; 122: 581-3. (Pubitemid 35002139)
90. Agarwal R, Agarwal AN, Gupta D,. Efficacy and safety of iodopovidone pleurodesis through tube thoracostomy. Respirology 2006; 11: 105-8.
91. Agarwal R, Aggarwal AN, Gupta D, et al,. Efficacy and safety of iodopovidone in chemical pleurodesis: a meta-analysis of observational studies. Respir. Med. 2006; 100: 2043-7. Epub 2006 Mar 30. (Pubitemid 44490275)
92. Kelly-Garcia J, Roman-Berumen JF, Ibarra-Perez C,. Iodopovidone and bleomycin pleurodesis for effusions due to malignant epithelial neoplasms. Arch. Med. Res. 1997; 28: 583-5. (Pubitemid 28014275)
93. Agarwal R,. Iodopovidone: an inexpensive and effective agent for chemical pleurodesis [letter]. Lung Cancer 2007; 55: 253-4. (Pubitemid 46074230)
94. Foresti V,. Intrapleural Corynebacterium parvum for recurrent malignant pleural effusions. Respiration 1995; 62: 21-6.
95. Hillerdal G, Kiviloog J, Nou E, et al,. Corynebacterium parvum in malignant pleural effusion: a randomized prospective study. Eur. J. Respir. Dis. 1986; 69: 204-6. (Pubitemid 16017362)
96. McLeod DT, Calverley PM, Millar JW, et al,. Further experience of Corynebacterium parvum in malignant pleural effusion. Thorax 1985; 40: 515-18. (Pubitemid 15026220)
97. Senyigit A, Bayram H, Babayigit C, et al,. Comparison of the effectiveness of some pleural sclerosing agents used for control of effusions in malignant pleural mesothelioma: a review of 117 cases. Respiration 2000; 67: 623-9. (Pubitemid 32008888)
98. Chella A, Ribechini A, Dini P, et al,. Treatment of malignant pleural effusion by percutaneous catheter drainage and chemical pleurodesis [in Italian]. Minerva Chir. 1994; 49: 1077-82.
99. Barbetakis N, Antoniadis T, Tsilikas C,. Results of chemical pleurodesis with mitoxantrone in malignant pleural effusion from breast cancer. World J. Surg. Oncol. 2004; 2: 16-22.
100. Barbetakis N, Vassiliadis M, Kaplanis K, et al,. Mitoxantrone pleurodesis to palliate malignant pleural effusion secondary to ovarian cancer. BMC Palliat. Care 2004; 3: 4.1186.
101. Shaw P, Agarwal R,. Pleurodesis for malignant pleural effusions. Cochrane Database Syst. Rev. 2004; (1): CD002916.
102. Tan C, Sedrakyan A, Browne J, et al,. The evidence on the effectiveness of management for malignant pleural effusion: a systematic review. Eur. J. Cardiothorac. Surg. 2006; 29: 829-38.
103. Debeljak A, Kecelj P, Triller N, et al,. Talc pleurodesis: comparison of talc slurry instillation with thoracoscopic talc insufflation for malignant pleural effusions. J BUON. 2006; 11: 463-7. (Pubitemid 46729860)
104. Ong KC, Indumathi V, Raghuram J, et al,. A comparative study of pleurodesis using talc slurry and bleomycin in the management of malignant pleural effusions. Respirology 2000; 5: 99-103. (Pubitemid 30434955)
105. Brant A, Eaton T,. Serious complications with talc slurry pleurodesis. Respirology 2001; 6: 181-5. (Pubitemid 32896547)
106. Medford AR, Maskell NA,. A national survey of oncologist and chest physicians' attitudes towards empirical anti-oestrogen therapy, early pleurodesis and preference of sclerosing agent in malignant breast and ovarian pleural disease. Palliat. Med. 2005; 19: 430-1. (Pubitemid 41150273)
107. de Campos JR, Vargas FS, de Campos Werebe E, et al,. Thoracoscopy talc poudrage: a 15-year experience. Chest 2001; 119: 801-6. (Pubitemid 32197651)
108. Scalzetti EM,. Unilateral pulmonary edema after talc pleurodesis. J. Thorac. Imaging 2001; 16: 99-102. (Pubitemid 32231703)
109. Viallat JR, Rey F, Astoul P, et al,. Thoracoscopic talc poudrage pleurodesis for malignant effusions: a review of 360 cases. Chest 1996; 110: 1387-93. (Pubitemid 26425133)
110. Weissberg D, Ben-Zeev I,. Talc pleurodesis. Experience with 360 patients. J. Thorac. Cardiovasc. Surg. 1993; 106: 689-95. (Pubitemid 23310449)
111. Noppen M,. Who's (still) afraid of talc [editorial]? Eur. Respir. J. 2007; 29: 619-21. (Pubitemid 46554608)
112. Janssen JP, Collier G, Astoul P, et al,. Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study. Lancet 2007; 369: 1535-9. (Pubitemid 46670303)
113. Reddy C, Ernst A, Lamb C, et al,. Rapid pleurodesis for malignant pleural effusions: a pilot study. Chest 2010; 139: 1419-23.
114. Olden AM, Holloway R,. Treatment of malignant pleural effusion: PleurX catheter or talc pleurodesis? A cost-effectiveness analysis. J. Palliat. Med. 2010; 13: 59-65.